-
Report details
-
17
Figures
-
4
Tables
-
Market Analysis: POC COVID-19 Testing
-
Overview of POC COVID-19 Testing
-
Market Outlook
-
Setting Market
-
Top Company Briefs
-
Abbott
-
Roche
-
Quidel
-
Becton Dickinson
-
Executive News Briefing
-
Pathware Appoints New CEO
-
Mainz Biomed Appoints New COO
-
Personalis Appoints New VP of Diagnostic Sales
-
Financial Highlights: bioMérieux, Guardant Health, Lucira Health
-
bioMérieux Full-Year Sales up 10.5% in 2021 Like-for-Like
-
Guardant Reports Growth in Clinical (+38.5%) and Biopharma (+16.5%) Test Volumes
-
Lucira Health Reports First Full Year of Commercialization
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
-
Partnerships and Collaborations
-
Mergers and Acquisitions
-
Industry Watch
-
Region Watch
-
Broad-based Company Announcements
-
Biomerica Submitted H. pylori Test to FDA
-
Bruker Launches New LiquidArray Multiplex PCR Assays
-
C2i Genomics Launched MRD Test in Europe
|
In Vitro Diagnostics Business Outlook: Volume 1, Issue 14 - Point-of-Care (POC) COVID-19 Testing
9 May 2022
A new twice-monthly publication dedicated to IVD, In Vitro Diagnostics Business Outlook offers the following:
• Market Sizing and Forecasting of IVD Market Segments in Every Issue
• Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care–Updates on the Important Test Categories You Need to Know About
• Industry Watch – Developments with COVID-19 and Other Testing
• M&A, Distribution, Partnerships Tracked and Charted
• New Product Introductions and Company Announcements
• Company Profiling and Quarterly Results Summaries
• Regional Market Coverage
Page Count: 39
Table of Contents
-
Market Analysis: POC COVID-19 Testing
-
Overview of POC COVID-19 Testing
-
Market Outlook
-
Setting Market
-
Top Company Briefs
-
Abbott
-
Roche
-
Quidel
-
Becton Dickinson
-
Executive News Briefing
-
Pathware Appoints New CEO
-
Mainz Biomed Appoints New COO
-
Personalis Appoints New VP of Diagnostic Sales
-
Financial Highlights: bioMérieux, Guardant Health, Lucira Health
-
bioMérieux Full-Year Sales up 10.5% in 2021 Like-for-Like
-
Guardant Reports Growth in Clinical (+38.5%) and Biopharma (+16.5%) Test Volumes
-
Lucira Health Reports First Full Year of Commercialization
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
-
Partnerships and Collaborations
-
Mergers and Acquisitions
-
Industry Watch
-
Region Watch
-
Broad-based Company Announcements
-
Biomerica Submitted H. pylori Test to FDA
-
Bruker Launches New LiquidArray Multiplex PCR Assays
-
C2i Genomics Launched MRD Test in Europe
|
More information about this product
Other Users Also Viewed
8 May 2020
Outsourcing drug discovery is the beginning phase of the drug development process. Through outsourcing portions of their drug discovery programs, many pharmaceutical and biotechnology companies have found an effective cost-cutting strategy that can…
|
